TD Asset Management Boosts Stake in Krystal Biotech

Institutional investor increases position in gene therapy company

Mar. 3, 2026 at 7:31am

Got story updates? Submit your updates here. ›

TD Asset Management Inc. has increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 124.5% in the third quarter, according to a recent SEC filing. The firm now owns 45,080 shares of the company's stock, worth $7.958 million. Several other hedge funds and institutional investors have also added to or reduced their positions in Krystal Biotech in recent quarters.

Why it matters

Krystal Biotech is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. The increased investment by TD Asset Management suggests institutional confidence in the company's pipeline and future prospects.

The details

According to the SEC filing, TD Asset Management purchased an additional 25,000 shares of Krystal Biotech during the third quarter, bringing its total position to 45,080 shares. The firm now owns 0.16% of the company's outstanding stock. Other notable investors that have made changes to their Krystal Biotech positions include Bessemer Group Inc., which added 77 shares, and First Horizon Advisors Inc., which increased its stake by 212.8%.

  • TD Asset Management increased its position in Krystal Biotech during the 3rd quarter of 2026.

The players

TD Asset Management Inc.

An institutional investor that manages a portfolio of assets, including a position in Krystal Biotech.

Krystal Biotech, Inc.

A clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by TD Asset Management in Krystal Biotech suggests that institutional investors see potential in the company's gene therapy pipeline and are bullish on the stock's future performance.